It is well-accepted that maternal obesity affects fetal development to elevate the risk of offspring disease, but how this happens is unclear. Understanding placental alterations during gestation as a consequence of maternal obesity is critical to understanding the impact of maternal obesity on fetal programming. Here, we used histological criteria, flow cytometry, quantitative PCR, and multiplex cytokine assays to examine changes in cell proliferation and inflammation in the placenta during gestation in a mouse model of maternal high-fat dietinduced obesity. We focused on mouse mid-to late gestation (approximately human late first and third trimester) because previous literature has indicated that this is when important regulators of metabolism, including that of the brain and endocrine pancreas, are forming. These studies were undertaken in order to understand how maternal obesity changes the placenta during this period, which might suggest a causal link to later-life metabolic dysfunction. We found that labyrinth thickness and cell proliferation were decreased at both pregnancy stages in obese compared to normal weight pregnancies.
INTRODUCTION
An estimated 1.5 billion people worldwide are classified as obese [1] . Obesity is frequently comorbid with type 2 diabetes, hypercholesterolemia, hyperinsulinemia, and cardiovascular disease-a suite of disorders collectively referred to as the metabolic syndrome [2, 3] . Efforts to thwart the onset and progress of obesity have focused to date on individuals who already are overweight, but success rates have been poor with, on average, only 15% of patients losing significant weight following dietary or lifestyle modifications [4] . Recently a growing body of research on both human and animal subjects has revealed that obesity during pregnancy can clearly and substantively elevate the risk that offspring will exhibit deregulated body weight regulation and develop obesity [5] [6] [7] [8] [9] . This has led to the concept of developmental programming of obesity, wherein it is envisioned that the developing fetus is affected by some as-yet-unknown factors that are produced as a consequence of maternal obesity [10] . Critically, the identity of such influential factors, their origin, and how they affect the fetus to elevate the risk of offspring obesity are almost completely unknown.
Obesity is associated with chronic low-grade inflammation, including elevated numbers of immune cells, such as macrophages, and cytokines [11] [12] [13] [14] [15] [16] [17] . A variety of cytokines, including, interleukin 1 beta (IL1B), interleukin 6 and 10 (IL6 and IL10), monocyte chemoattractant protein 1 (MCP1), interferon gamma (IFNG), and tumor necrosis factor (TNF) have been observed to be elevated in association with obese pregnancy in both humans and rodents [18] [19] [20] [21] . Reports also indicate that obesity-associated maternal cytokines may gain access to the fetus by way of the placenta [22, 23] , and still others suggest that maternal inflammation is able to initiate an inflammatory response in the placenta itself [24] [25] [26] [27] . Together this work points to the placenta as a critical player in relaying the pathological maternal obesity physiology to the fetus. Whether the placenta is an active player that produces its own factors that affect the fetus or acts passively, by merely allowing the passage of maternal signals, is unknown. Unfortunately, much of our knowledge of the placenta comes from studies of human term placenta [18, 20, 25, 28] . However, understanding the timing and nature of changes to the placenta, particularly its inflammatory state, across the obese pregnancy is critical for the development of interventions aimed to prevent or reduce fetal programming. In particular, if we consider that later life physiology can be affected by events occurring during the fetal period, then it is important to relate physiological changes that occur during gestation to the timing of the formation of the organ systems of interest. We are interested primarily in understanding the formation of the fetal brain regions that regulate body weight later in life, which in the mouse develop between Gestational Day (GD) 15.5 (Carnegie stage 22, equivalent to human day 55 [29] ) and GD 17.5 (1.5 days before term) [30, 31] . Thus, we focused on these two ages in the study reported here.
Rodent models of diet-induced obesity from high-fat diet (HFD) feeding before pregnancy [32] or at the time of conception [8] can program obesity and the metabolic syndrome in the offspring. Here, we have used a rodent model of maternal obesity [32] to investigate whether and how placental development may be altered. Specifically, we have examined placental layer thickness and composition, which may serve as a proxy indicator of placental function, cell proliferation, macrophage abundance and activation state, and cytokine production across pregnancy, and found both age-and sex-specific changes to these parameters. These results further implicate the placenta in later-life offspring disease risk and help define important developmental windows and sex-specific changes that support a potential role for placental inflammation in maternal obesity programming of offspring disease.
MATERIALS AND METHODS

Animals
All the animal procedures were approved by the Animal Ethics Committee, University of Otago. Mice (C57BL/6) were housed under 12L:12D cycle (lights on at 0600 h) with ad libitum access to food and water until dietary intervention began at 4 wk of age, when female mice were weighed and randomly assigned into two dietary groups receiving either a control diet (10% kcal fat, 3.85 kcal/gm, D12450B; Research Diets) or a HFD (45% kcal as fat, 4.73 kcal/gm, D12451; Research Diets). Details of the diets can be obtained at http://www.researchdiets.com/opensource-diets/stock-diets/dio-series-diets. Mice were weighed weekly and fed their assigned diet for 8 wk, when all HFDfed animals were not only significantly heavier than matched controls (Supplemental Fig. S1A ; all the supplemental data are available online at www.biolreprod.org), but also were !30% heavier and thus considered obese (Supplemental Fig. S1B ). Mice were time-mated with chow diet-fed males of normal body weight, and the day of vaginal plug detection was considered GD 0.5.
Tissue Collection and Processing
All the fetuses and placentas were collected before 1000 h. Dams were sacrificed using cervical dislocation, fetuses along with their placentas were removed and placed on ice, and placentas were then dissected free and processed further for histology, quantitative PCR (qPCR), or immune cell quantification as detailed below in the relevant sections. Only dams with 7-10 fetuses/litter were included. All the histological staining was performed by the Histology Unit, Department of Pathology, University of Otago. For all the analyses in which the sexes were combined, an equal number of placentas from male and female fetuses were used.
For hematoxylin and eosin staining, placentas were fixed in 10% neutralbuffered-formalin overnight at room temperature, embedded in wax, and sectioned in the vertical plane at 3 lm thickness. From the point at which all three layers-decidua, junctional zone (including trophoblast giant cells and spongiotrophoblast cells), and labyrinth-were clearly visible (layers defined as previously described [33] ) (Supplemental Fig. S2A ), groups of four consecutive sections were then collected at 600, 800, and 1000 lm for GD15.5, and at 2000, 3000, and 4000 lm for GD17.5.
Histology and Data Analysis
Slides were analyzed under a Olympus AX70 light microscope and photographed using MicroPublisher 5.0 (QImaging). The width (x-axis) of the placenta was calculated by measuring the length from one side of decidua to the other (Supplemental Fig. S2B ), and the thickness (y-axis) of the placenta was measured from the outermost edge of the decidua to the outermost edge of the labyrinth, bounded by the chorion, at the thickest point (Supplemental Fig.  S2B ). All the measurements were taken using ImageJ (v. 1.45s, National Institutes of Health). Layers were measured in three equally spaced locations across the width of the placenta (Supplemental Fig. S2B ). To normalize for differences in total thickness among the measurement points, individual layer thickness was expressed as a percentage of total thickness at each point, and the percentages were averaged across all the measurements. For each dietary condition, a total of 12 placentas (taken from three independent pregnancies) were used.
Phosphohistone H3 Immunohistochemistry
Placentas were fixed and sectioned as described. For each age, 16 control and 16 maternal HFD (MHFD) placentas were collected from across four independent litters. Tissue sections were incubated in PBS containing 40% methanol (Merck) and 1% H 2 O 2 (Sigma-Aldrich Corp.) to quench endogenous peroxidase activity, washed in PBS, and incubated overnight at 48C in primary rabbit anti-phosphohistone H3 (pH3) antibody (1:1000; Millipore) with 3% normal donkey serum (Sigma-Aldrich) and 3% bovine serum albumin (SigmaAldrich). Sections were then washed in PBS and incubated with biotinylated donkey anti-rabbit antibody (1:200; Jackson ImmunoResearch Laboratories) and then with Vectastain ABC kit (1:100; In Vitro Technologies) for 90 min each at room temperature. Immunoreactivity was revealed with 3,3 0 -diaminobenzidine (Sigma-Aldrich), and the sections were then counterstained with hematoxylin. Immunostained placenta sections were observed under a Olympus AX70 light microscope, and photos were captured using MicroPublisher 5.0. ImageJ was used to separate hematoxylin (blue) and 3,3 0 -diaminobenzidine (brown) staining, and the numbers of immunostained cells were then counted in each of the placental layers.
Flow Cytometry
Placentas were collected as described, placed in 40 lm cell strainers (Becton Dickinson), and gently dispersed into a single cell suspension using a 1 ml syringe (Becton Dickinson) as previously described [34, 35] . Red blood cells were lysed in buffer containing 155 mM NH 4 Cl, 10 mM KHCO 3 , and 0. , and F4/80 þ cells were analyzed. Unstained samples and fluorescence minus one controls were used to create gates as previously described [36, 37] . Data acquisition was performed using Gallios (Beckman Coulter) and analyzed using Kaluza Flow Cytometry Analysis Software (v1.2, Beckman Coulter).
RNA Preparation, cDNA Synthesis, and Quantitative Reverse Transcription-PCR
Placentas were collected as previously described. RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen) using TissueLyser II (Qiagen) and purified using mini spin columns following the kit protocol for extracting RNA from animal tissues. Total RNA was eluted in RNase-free H 2 O and quantified spectrophotometrically (Nanodrop 2000; Thermo-Scientific) to assess RNA purity. RNA was DNase treated (Ambion DNA-free kit; Life Technologies) following the manufacturer's protocol, and 2 lg RNA was used to create cDNA using Invitrogen's Superscript III First Strand Synthesis System (Life Technologies), following the manufacturer's protocol, and primed using both random hexamers and oligo-dTs. A reaction without reverse transcriptase was also run alongside the experimental samples to eliminate DNA or RNA false positives. Primers (amplicon length: 100-200 base pairs; Integrated DNA Technologies) were designed using National Center for Biotechnology Information's primerBLAST (http://www.ncbi.nlm.nih.gov/tools/primerblast), or from previous literature, and can be obtained in Supplemental Table S1 .
A range of primer concentrations (50-500 nM) were tested on the placental cDNA, and each PCR product was run on a 1.5% agarose gel (Sigma-Aldrich) to verify the specificity of the PCR product. Primer efficiency was tested on five 10-fold dilutions of placental cDNA and the reaction efficiency was calculating using: Efficiency ¼ 10 3 (À1/slope)
À1
. All the primers were used at 100-300 nM concentrations and were between the accepted range of efficiency (85%-100%) [38] .
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All the qPCR was carried out with the LightCycler 480 Real Time PCR System (Roche), using SybrGreen chemistry, and white 96-well plates (Roche). Each individual reaction was run in triplicate and contained: 10 ll 23 SybrGreen mastermix (Bioline), 2 ll forward and reverse mixed primer (see Supplemental Table S1 for concentrations), 6 ll H 2 O (molecular grade; Invitrogen) and 2 ll cDNA (14 ng). The following LightCycler protocol was used: 958C for 10 min (preincubation); 45 cycles of 958C for 10 sec, 608C for 1 min and 728C for 30 sec (amplification); 958C for 1 sec, 508C for 1 min (melting curve); and 408C for 30 sec (cooling). All the qPCR runs also included two types of negative control: 1) no reverse transcriptase and 2) no cDNA. All the reaction products reported here showed crossing values 32 cycles. Quantification cycles were generated using the second derivative maximum method (LightCycler 480 Software; Roche), and the Pfaffl-relative quantification equation [39] was used (with efficiency correction for different primers) to calculate the expression of the target gene relative to the reference genes. PGK1 and GAPDH, as selected with NormFinder [40] , were used as reference standards. For controls, technical replicates of each control group were used to measure the variance as previously described [41] , and two-way ANOVA was then used to compare the significance in the C t values among the groups.
Multiplex Cytokine Assay
Cytokine protein levels were measured from maternal and fetal blood plasma samples at GD15.5 and GD17.5 in both dietary groups using 6-Plex assay (Bio-Plex Pro mouse cytokine Th17 Panel A; Bio-Rad) to look for IL1B, IL6, IFNG, IL10, IL17A, and TNF protein. Maternal blood samples were collected following decapitation using EDTA-coated (K 2 EDTA, 1-2 mg/ml) microcapillary tubes (Innovative Med Tech). For GD15.5 fetuses, blood samples were collected from the general circulation and the liver, which acts as a transient hematopoietic organ during development and provides a concentrated source of blood, following decapitation [42, 43] . For GD17.5 fetuses, blood samples were collected from the general circulation only following decapitation. Litters with between 6-8 fetuses were used to collect both maternal and fetal blood samples, and the whole litter was pooled to collect the fetal blood samples.
Microcapillary tubes were then centrifuged to collect blood plasma samples, and these samples were transferred to the endotoxin-free tubes (Axygen Scientific) and then stored at À808C until the assay. Cytokine assay was prepared as per manufacturer's protocol with each sample being run in duplicate; the assay was run using Bio-Plex 200 system (Bio-Rad). The assay data was analyzed with Bio-Plex Manager Software (v6.0; Bio-Rad), and the analyte concentrations were calculated in pg/ml based on the standard curve dilutions.
Statistical Analysis
All data are presented as mean 6 standard error of the mean (SEM). Data collected from control and MHFD placentas were pooled by pregnancy and compared statistically within age using a two-tailed unpaired t-test (GraphPad Prism 5; GraphPad) to calculate differences between dietary groups. P , 0.05 was considered significant. For cytokine mRNA quantification (qPCR) and flow cytometry, two-way ANOVA with Bonferroni post hoc test was performed in order to compare diet versus sex and diet versus age, and P , 0.05 was considered significant. G*Power 3 (v3.17) [44] was used to test statistical power and thus determine the power/relevance of biological significance in all conducted experiments. All the results reported as significant had 80% power or higher. For all the experiments where the placental or fetal material was pooled, the replicates were pooled by pregnancy, that is, all placentas or fetuses from the same mother were averaged to make n ¼ 1, rather than being treated individually as replicates.
RESULTS
Effects of HFD on Maternal Body Weight and Inflammation
Female mice gained significant body weight as early as 1 wk after being placed on a HFD (P , 0.05, Supplemental Fig.  S1 ). Maternal obesity was also associated with significant elevation of the following cytokines-IL6, IL1B, IL10, IL17A, IFNG, and TNF-in maternal blood plasma at GD15.5 and GD17.5 of pregnancy compared with controls (Supplemental Table S2 ). Maternal obesity resulted in significantly increased placental weight at GD 15.5 and fetal body weight at GD17.5 (Supplemental Fig. S3 ). However, the number of fetuses per litter and their sex ratio (male/female) remained unchanged in obese compared to normal weight pregnancies (Supplemental Table S3 ).
MHFD Altered Layer Thickness
Maternal obesity did not result in significant differences in either the overall width or thickness of the placenta compared with controls (data not shown). Also, in both control and MHFD placentas, the normal age-related increase in the labyrinth thickness at the expense of the junctional zone appears to have occurred between GD15.5 and GD17.5 [45] . The thickness of the individual layers was, however, altered by maternal obesity. At both GD15.5 (Fig. 1, A-C) and GD17.5 ( Fig. 1, D-F) , maternal obesity resulted in significantly decreased labyrinth thickness and a concomitant increase in decidua thickness (see also Table 1) . No significant differences between male and female placentas were observed for either of the dietary conditions. 
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MHFD Reduced Cell Proliferation in the Placenta
Altered layer thickness and morphological changes raised the possibility that cell proliferation or apoptosis may be altered in the placentas of obese dams. Cell proliferation was examined by staining with an antibody to pH3, which labels cells in the S-phase of the cell cycle [46] (Fig. 2) . At both GD15.5 (Fig. 2,  A-D) and GD17.5 (data not shown), the majority of pH3-stained cells were restricted to the labyrinth, mainly the cytotrophoblast cells (Fig. 2, A-D) . At both GD15.5 and GD17.5, the number of cells in S-phase within this region was significantly reduced in placentas from obese dams compared to controls (Fig. 2E) . No significant differences between male and female placentas were observed for either of the dietary conditions.
Apoptosis was examined by staining with an antibody to activated caspase-3. Very few cells labeled with caspase-3 in either normal or MHFD placenta, indicating that apoptosis is not a physiological or pathological mechanism used to modulate cell number in the placenta, at least at the stages examined (data not shown).
MHFD Alters Macrophage Activation and Cytokine Production in the Placenta
We next were curious to discover whether MHFD altered the inflammatory state of the placenta, and if so, when this KIM ET AL.
occurred during gestation. Initially, we characterized the immune cells present and their relative abundance. We used flow cytometry, the standard immunological technique for determining immune cell abundance, to select firstly for CD45 þ , which, with the pan-isoform antibody used here, labels mixed lineage cells, including lymphocytes and monocyte/macrophages. This population was then assayed for the presence of cells in the following lineages: B-cell (B220 þ ), T-cell (CD3 þ ), natural killer (NK) cells (CD49b þ ), and monocyte/macrophage (F4/80 þ ). There were no differences in B, T, or NK cells between MHFD and control placentas at either age (Fig. 3, A and B) , however the relative abundance of monocyte/macrophage lineage cells (F4/80 þ ) dropped significantly between the two ages irrespective of dietary modification (Fig. 3C) .
Monocyte/macrophage lineage cells may become activated and increase cytokine expression without proliferating [20, 47] , so it was important also to determine whether their activation state was increased by MHFD. To do this, we assessed mRNA expression of Cd11b, a marker of activated type 1 and 2 macrophages [48, 49] . Cd11b expression was unchanged by MHFD compared to control placentas at GD15.5 ( Fig. 4A) , but was increased significantly by MHFD compared to controls at GD17.5 (Fig. 4B) . Thus, macrophage activation in the placenta appears to be increased by MHFD in late gestation.
Having established that macrophage activation state was changed by MHFD, we predicted that this would be reflected in altered cytokine gene expression. Cytokine gene expression at GD15.5 ( Fig. 4C) was unchanged, but tended toward a reduction, consistent with the reduced macrophage activation at this age. By contrast, at GD17.5 (Fig. 4D) , expression was elevated in MHFD compared to controls for Il6, Il1b, Tnf, and Il10, consistent with the increase in macrophage activation at this age. Thus, increased placental macrophage activation is reflected in increased cytokine expression in the placenta in response to MHFD at the later stages of gestation.
MHFD Alters Circulating Cytokine Levels in the Developing Fetus
We were next interested to understand whether MHFD would result in cytokine protein elevation in the fetal circulation at either gestational age. Of the cytokines examined (IL1B, IL6, IL10, IL17A, IFNG, and TNF), only IL17A levels were significantly changed (reduced) in the fetal circulation of MHFD pregnancies at GD 15.5 compared to controls (Fig. 5 , A, C, E, G, I, and K). At GD17.5, IL6 [50] , IL17A, and IFNG were significantly elevated in the fetal circulation of MHFD pregnancies compared to controls (Fig. 5, D, H, and J) ,while the other cytokines (IL1B, IL10, and TNF) remained unchanged (Fig. 5, B, F, and L) .
Sex-Specific Changes in Inflammation in MHFD Placentas
Because fetal programming of later-life disease by a mother's obesity is often seen to have sex-specific effects [9, 51, 52] , we sought to determine whether the changes in placental inflammation were sexually dimorphic. In MHFD placentas of male fetuses, macrophage activation was unchanged at GD15.5 ( Fig. 6A ) but was significantly increased at GD17.5 (Fig. 6B) . In MHFD placentas of female fetuses, 
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macrophage activation was significantly decreased at GD15.5 ( Fig. 6C) and increased significantly at GD17.5 (Fig. 6D) .
Cytokine mRNA changes in the placenta paralleled changes in macrophage activation state in both sexes at both ages. The MHFD placentas of male fetuses at GD15.5 showed unchanged cytokine expression (Fig. 7A ), but at GD17.5, they showed increases in Il1b, Tnf, and Il10 (Fig. 7B) . By contrast, the MHFD placentas of female fetuses at GD15.5 showed reduced expression of IL6, IL1b, Tnf, and IL10 and no changes in the other cytokines examined (Fig. 7C) . At GD17.5, IL1b and Il10 were increased, while the others remained unchanged (Fig.  7D) . Thus, differences in macrophage activation and consequent cytokine expression that occur in the placenta in response to MHFD appear to be age-and sex-specific.
DISCUSSION
We have observed a number of significant changes to the mid-to late gestational placentas of obese female mice fed a HFD, which may help clarify the role of the placenta in developmental programming of later-life offspring disease. Initially, we examined the histology of placental layers and observed that the placentas of obese mothers had a small labyrinth phenotype, owing at least in part to reduced cell division in the labyrinth trophoblast cells. Cytotrophoblast cells fuse to form the syncytiotrophoblast [53] , and thus a reduced number of cytotrophoblasts may indicate reduced syncytiotrophoblast formation and consequent placental dysfunction. Although there are no studies to our knowledge that have specifically investigated trophoblast cell proliferation in obese pregnancies, pregnancies complicated by preeclampsia and intrauterine growth retardation, which are also associated with fetal programming of obesity, both exhibit reduced syncytium formation [54] . The observation that these disorders of pregnancy, including maternal obesity, all elevate offspring obesity risk hints at a common mechanism for obesity programming based on cellular changes occurring in the placenta. Whether the underlying molecular mechanisms may be shared or unique to each disorder remain for further investigation.
We showed here that cytokine production and the activation state of placental macrophages were altered by maternal obesity, while the abundance of macrophages remained unchanged. These observations are consistent with macrophage activation in other tissues of the body, which is accompanied by upregulation of cytokine production in the absence of cell proliferation [20, 47] . Several of the cytokines showed expression patterns that have already been described in human term placenta, and the data presented here are consistent with those [25] . One of the most striking changes is that of IL17A, which is reduced early and elevated late in gestation in the circulation of fetuses of obese mothers compared to controls. IL17A has previously been reported to be elevated in obesity [55] , and our findings of elevated IL17A in the maternal circulation is consistent with this. In peripheral tissues, IL17A is derived from Th17 cells following stimulation by inflammatory cytokines, including IL6 [56] . Thus, at GD17.5, the elevation of IL17A in the circulation of fetuses from obese mothers could result from IL6-dependent increase in Th17 cells within the fetal circulation, with stimulatory IL6 derived from mother, placenta, or fetus. One possibility is that IL17A tracks with fetal size as a reflection of adiposity. Although this does not seem to be the case with all of the cytokines examined, which vary independently of fetal size, fetal adiposity may be a factor for IL17A. The reduction in IL17A in the GD15.5 circulation of fetuses from obese mothers is more curious, but if IL17A expression is dependent upon IL6 for expression, reduced IL17A may have to do with the low levels of IL6 expression at this stage. However, there are also reports of IL17A affecting IL6 expression in some tissues, indicating a high degree of complexity to this system [57] and requiring further examination well beyond the scope of this study.
It is interesting that upregulation of proinflammatory cytokines, such as IL1b, IL6, IL17A, and TNFa, is accompanied in the placenta by upregulation of the modulatory, sometimes considered anti-inflammatory, IL10. The exact role of IL10 in the placenta is unknown, but one possibility is that its upregulation may be part of an intrinsic protective FIG. 5. Maternal obesity elevates cytokine protein expression in the developing fetus. Bar graphs showing mean 6 SEM cytokine protein level (pg/ml) for fetuses from control mothers (white bars) and those from obese mothers eating a HFD (black bars) at GD15.5 (A, C, E, G, I, and K) and GD17.5 (B, D, F, H, J, and L). *P , 0.05, **P , 0.01. Numerals at the base of bars indicate number of pregnancies (n ¼ 6 for each) for which fetal plasma was collected and pooled for analysis.
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mechanism to dampen down the obesity-driven inflammation. IL10 has been described to be expressed by trophoblast cell lines in vitro [58] , suggesting that in vivo this cell population may be responding to macrophage-secreted proinflammatory molecules by secreting the anti-inflammatory IL10. However, it is also possible that the IL10 secretion derives from the macrophages themselves. Type 2 macrophages are known to have anti-inflammatory function and secrete IL10 [59] , so our results may suggest that type 2 macrophages preferentially become activated in MHFD placenta. A final possibility is that the placental macrophages may not have a clear type 1 or type 2 phenotype. This unconventional phenotype (expressing markers for both type 1 and type 2) has been previously reported in the nonplacental portion of decidual macrophages in humans and in brain microglia during the early postnatal period in rodent models [60, 61] . Irrespective of which cells express IL10, this anti-inflammatory cytokine has been previously shown to reverse lipopolysaccharide-induced fetal growth restriction [62] , again hinting that elevated IL10 may be an anti-inflammatory protective mechanism that is initiated in the placenta in response to elevated inflammatory cytokines. A better understanding of which cells express IL10 and manipulating IL10 receptor expression or IL10 production would help further to evaluate the role of IL10 in pregnancies complicated by obesity.
In addition to the changes in cytokine levels in MHFD placenta, the circulating cytokines in the developing fetus were elevated at GD17.5, but not at GD15.5, by MHFD, and these changes corresponded to changes in cytokine levels in the placenta. This is consistent with previous studies that have observed elevated cytokines in both human and mouse maternal obesity [18] [19] [20] [21] . Whether maternal cytokines are transferred to the fetus is a speculation that has met with some controversy because it may also be possible that the placenta amplifies, dampens, or otherwise transforms maternal inflammation so as to gate the inflammatory environment that the fetus is exposed to. We have observed that inflammatory markers in the fetus do not change until GD17.5 despite elevated maternal inflammation much earlier. This suggests that the placenta, at least up until GD17.5, is able to protect the developing fetus from elevated maternal inflammation and is consistent with the placenta functioning as a protective, potentially immunosuppressive, organ [60, 61] .
Notably, the changes in cytokine expression or abundance that we have observed do not appear to be due to proportionate changes in either placental or fetal size. For example, at GD15.5, the MHFD placenta is larger than control, and yet we see no concomitant increase in any placental parameters measured. Similarly, at GD17.5, the MHFD fetus is larger than control, and although some cytokines are elevated, others are not. Also at GD17.5, there is no difference in the size of the placenta, yet placental cytokine expression is higher in MHFD pregnancies compared to controls. These disparities suggest that some level of regulation independent of fetal or placental size is occurring.
Perhaps the most striking observation in this study is that of sex differences in macrophage activation and cytokine gene expression in MHFD placentas. There is controversy in the literature regarding sex-specific programming of offspring obesity and the metabolic syndrome by maternal obesity, with some studies showing no sex differences [9] , some showing a larger impact on female offspring than male [63, 64] , and still others showing a larger impact on male offspring [52] . Our finding that male placentas showed greater inflammation and macrophage activation than females supports a mechanism by which male offspring could be more affected by the downstream consequences of these factors. Considering that the programming of offspring obesity by maternal obesity is multifactorial, it is likely that multiple factors that affect multiple physiological systems might individually have sexspecific effects. This is not surprising given differences in male and female physiology even at these stages of development. For example, GD15.5 female placentas showed significant reductions in macrophage activation and cytokine production that were not evident in males, suggesting that female placentas more readily compensate for maternal obesity or that they possess fundamentally different cellular and gene expression responses to environmental stimuli. This is consistent with a recent study that found that gene expression was sexually dimorphic in normal placentas (genes other than those we FIG. 6 . Macrophage activation state in response to maternal obesity is sexually dimorphic. Bar graphs showing mean 6 SEM mRNA fold-change in MHFD (black bars) compared to the control group (white bars) at GD15.5 (A and C) and GD17.5 (B and D). Male (A and B) and female (C and D). *P , 0.05, **P , 0.01; n ¼ 12 placentas for each group. All the placentas were taken from at least three pregnancies.
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examined here) and that the gene expression changes in response to maternal HFD were also different between males and females [65, 66] . Similar sex-specific changes to placental physiology and gene expression have also been observed in other rodent models of maternal programming [67] . Thus, placental gene expression may be modulated differently by environmental factors in males and females. Unfortunately, we could not observe whether there was such sex differences in the circulating cytokine levels in the developing fetus because limited blood volume necessitated pooling the whole litter regardless of fetal sex.
The changes we and others have described occur before birth, during windows of fetal development when important metabolic tissues, such as the brain, liver, and muscle, are forming. Such changes may adversely affect the development of these tissues, perhaps impairing their function so that they work less efficiently later in life. Other recent studies have been undertaken to address similar issues regarding placental and fetal changes consequent to maternal obesity, and while some of the collective observations are consistent, there are also some differences. All the studies have shown the same overall effects of elevated inflammation and body weight in postnatal offspring in animal models, and this is consistent with epidemiological studies in humans. Thus, different animal models appear to represent, at least with respect to these parameters, appropriate models of human gestational obesity. However, the detailed molecular and cellular changes that take place appear to be somewhat variable from study to study. For example whereas ours and one other [68] showed fetal macrosomia, several other studies showed growth restriction, [69, 70] or fetal growth restriction with catch-up growth [71] . These differences may be partly due to differences in maternal age or composition of the obesogenic diet, in particular diet during gestation, as well as individual differences in glucose FIG. 7 . Cytokine changes in response to maternal obesity are sexually dimorphic. Bar graphs showing mean 6 SEM mRNA fold-change in placenta from MHFD (black bars) compared to the control group (white bars) at GD15.5 (A and C) and GD17.5 (B and D). Male (A and B) and female (C and D). *P , 0.05, **P , 0.01; n ¼ 12 placentas for each group. All the placentas were taken from at least three pregnancies.
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tolerance. Across these studies, the shared maternal endpoint was obesity at the time of mating, yet all the reports used slightly different maternal ages and fed slightly different diets or had different feeding protocols. This is important because other studies have shown that dietary parameters, such as protein and carbohydrate composition, can also affect placental physiology [72] . Another possible contributor to this variability in molecular and cellular changes is genetic background. Some wild-type mouse lines are more susceptible to obesity than others or display different physiological responses to an obesogenic diet [73] . Given that different maternal physiology accompanies obesity development in different genetic backgrounds, different mechanisms could also underlie elevated offspring obesity risk in these genetically diverse mice. In addition, many studies use naturally occurring or engineered mutant lines for their power in removing or altering genetic material [71] , but it is unclear whether such modifications may themselves affect the way that maternal, placental, and fetal physiology are affected by obesity and an obesogenic diet. Given this phenotypic heterogeneity and the fact that development itself is robust and malleable, one way of thinking about how our data fit into the existing literature is to consider that perhaps there is not one common molecular or cellular pathway to fetal programming of obesity, but potentially multiple pathways. The key players identified across all the systems, irrespective of species or model, appear to be inflammation and placental function, and disturbances in these systems, in their balance, or both. Thus, future research may focus on better understanding of the multiple, yet specific mechanisms that account for perturbation of these systems.
Here, we have examined a number of features of the placenta. Although there are changes in all of these parameters, the overall effect(s) on placental physiology are unclear. We believe that the combination of changes is likely to lead to altered placental physiology, but whether some changes are consequent to others or whether some changes are independent contributors to an overall pathology is not clear. Although requiring further investigation, the data presented here alongside already existing data provide clear direction for additional study into the role of the inflammatory response of the placenta to maternal obesity in the programming of laterlife offspring disease risk.
